Thought leaders from various cancer centers across the United States joined CancerNetwork® following the 2023 ASCO Annual Meeting to discuss highlights of the meeting in a game show–style production. EP. 1: 2-Minute Drill: The Biggest Surprise From the 2023 ASCO Annual Meeting Kristie L. Kah...
Home 2023 ASCO Annual Meeting Roche and Genentech at2023 ASCO Annual MeetingJune 02 - June 06 Chicago, USA am.asco.org Medical Materials Agenda Scientific Area Disease Area Date Type Personalized Healthcare Clear Jun 5 / Roche and Genentech SUNMO: A Phase III trial evaluating the...
During the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023), which took place in June in Chicago, Illinois, investigators presented the final results from the phase 1b/2 CARTITUDE-1 study (NCT03548207), which supported the February 2022 FDA approval of cilta-cel. CA...
OncoNano Medicine, Inc. today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, taking place June 2-6, 2023 at McCormick Place, Chicago, Illinois. Final results from Phase 2 study of pegsitacianine ...
2023年美国临床肿瘤学会(ASCO)年会将于2023年6月2日至6日在美国伊利诺伊州芝加哥以线上线下混合会议形式举行。 美国临床肿瘤学会年会(ASCO年会)是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议,汇集了众多世界一流的肿瘤学专家,和与会者们一起分享探讨当前国际最前沿的临床肿瘤学科研成果和肿瘤治疗技术,...
Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023)....
We highlight five key abstracts from the 2023 ASCO Annual Meeting that showcase these exciting updates in BCMA-directed CAR-T cell therapies in RRMM.To the editor B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment of relapsed and/...
GB491 (Lerociclib) has garnered international recognition at the 2023 ASCO annual meeting, which was successfully held in Chicago from 2 June to 6 June 2023:The research results of the LEONARDA-1 study were announced in the poster discussion session of the Metastatic Breast Cancer session ...
(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Ann...
“We believe that adding multi-cancer early detection testing to recommended screening is the best chance to address the growing burden of late-stage cancer in an aging population. We are excited to present new data at this year’s ASCO Annual Meeting supporting the use of GRA...